Friday, 26 July 2024

O.M (2019)

stupid we are?

Does this OM applies to him?

If applicable, How come the Admin of PCI the Secretary cum Treasurer did not refuse the Candidature of Dr B Suresh (Member of Council) under this order.

It looks the Secretary doesnt apply the mind.

What quality of people we have in Pharmacy Councils?

 
Why this OM came in media after his resignation ? 
All OM and informations used as and when required.

Wednesday, 24 July 2024

Creating a new Pharmacy service system in the Indian Healthcare system.

From,
Bhagwan P. S, B. Pharma, Frmr. Registrar, KSPC, Frmr. Dy Director (PHARMACY), HFW dept, Govt. Of Karnataka. 

• To
• The Secretary, 
• PCI, 
• Dear Archana. Mudagal ji, 
• Greetings & Good wishes. 

• Sub: Creating a Pharmacy service system in the Indian Healthcare system. 

• Well madam, as you are aware that an organized pharmacy service system does not exist in Indian healthcare system and as such pharmacists with different qualification, specialization and capabilities are deprived of an opportunity to serve in the healthcare sector.
• Needless to say the notifications you as Secretary PCI issuing from time to time including the ppr 2015 and it’s latest amendment hardly provides any clue or a clear roadmap for the policy makers and Bureaucrats  to consider or discuss. 

• Govt being the largest healthcare service provider in India needs to be apprised from all angles (1) structural, (2) functional with (3) financial implications. But we from PCI can provide the (1) and (2) leaving the (3) to the Government to decide. 

• Hence, with my experience and knowledge gained in Govt service I submitting to you a draft proposal to uplift the Indian healthcare system that needs and provides a comprehensive #Pharmacare support service for onward submission to the Govt of India. 

•# PharmaCare – A concept to upgrade Indian Healthcare System, 

👉Introduction
• Indian Healthcare system is a very huge and complex service system catering to ……. millions of people in India. The system involoves a massive preventive sector and an equally large curative sector. Considering the dictum that ‘The Medical care begins the moment the Healthcare fails’ the Govt of India is spending very heavily on the preventive sector to ensure the medical care is minimized as much as possible.
• Though the system to address the healthcare and medical care is in place there are some serious lacunae that are causing serious deficiencies in the servive that are just ignored or accepted on default but seldom assessed and openly admitted due to some obvious reasons.

• What the public are seeing and appreciating is glamorous looks and some relief they are getting with no knowledge of hidden threats of loaded molecules the consequences of which are just accepted to ignore or go in for one more round of treatment either as a new problem or an accepted ongoing exercise. 
• Indian medical practice is being very very poor in documentation it is humanly impossible to trace back and investigate to find out the trouble shooting black spot. So to say, the Indian medical practice is far behind #Evidence Based Therapy.

• Amidst the massive drugs movement that is happening the cry due to  scarcity of the vital drugs at the terminal service point and financial burden due to illogical vendor driven procurement  and the consequence wastage and demand for more and more funds is an equally a massive challenge.

• But, knowingly the Indian Healthcare system is continuing the weak traditional system and deliberately avoiding the solution that warrants professional management with Logistic Pharmacists and Clinical pharmacists.
• Situation analysis
• In India, we have a National Drug Policy which is industry oriented but not Healthcare oriented and we do not have a ‘National Medication Policy’ to ensure rationale and evidence-based medication. The National Health Policy document published annually seldom touches this problem and the need.
• Hence it is necessary for each healthcare professional and institution to be on their own guard, by study of literatures and maintaining their own clinical reports of drugs they use and monitor the compliance, results and Adverse Drug Events.
• ‘Pharmacovigilance’ is a figment of Clinical Pharmacy and is a  routine duty of the Clinical Pharmacist and to a lesser extent of the logistic pharmacist also including retail pharmacist. Somehow making it a National vertical program under CDSCO  is not convincing. 
• As per the data from AIOCD AWACS more than 3000 products are launched in India every year.  It is humanly impossible for any Clinician to understand and digest the intricacies of these new molecules. Formulations along with hundreds of ‘Me-too’ formulations let alone remembering their therapeutic indications, worthiness, possible toxicities, contraindications, incompatibilities etc.
• The irony is the clinicians prescribe the formulations that they never have seen but with the information they received.
👉 Drug Quality 
• Everybody wants Good medicine. What is good medicine? 1. The one that gives good relief, the one with least side or after effect/d, the one that is safe, the one is affordable and effective with least side or after effect. Law says a Good medicine is one that passes the tests of standard which is only a In-Vitro parameter. Clinical satisfaction and patients satisfaction is a variable factor though is important.
• It is true that drugs and formulations under go quality check while during process and also before being released into the market. That means each batch is as per standardized well tested and established procedure. 
• Unfortunately, the fact is:
• “What is tested is not available for use and what is available for use is a presumptive quality”. 
• Nothing wrong and it is inevitable but warrants only an additional care to keep evaluating at Clinical level too with due documentation of observations, experience and feedback on its affordability, acceptability, patients comfort, clinical or therapeutic response, Adverse events etc . But, these aspects of  therapy are observed and  experienced only in the clinic. 

• Clinicians changing their own prescription for unknown reason to a different make of a same molecule or formulation are almost an everyday happening at the cost of the patient. This is going on undocumented and nobody dares to question?. The Therapeutic quality assessment though variable from one Clinician to the other and one clinic to the other can also be standardized near to reliable accuracy through documentation which forms the backbone of pharmacare service. This documentation particularly at thr institutional level can for a part of the evaluation of tender while fixing Contract.
• This warrants an in-house comprehensive ‘Pharmacare’ department to carry out in-house evaluation of all the medication related issues so that what reaches the Clinician and the patient at least in and from an institution would be of a well-studied and clinically evaluated formulation. That ensures evidence-based medication therapy. 
• Clinicians are so hard pressed for time and the patient load being so heavy. It doesn’t allow any comfortable free time for them to do library and literature research to keep themselves abreast with the trend and true picture of the products they are using. They need an in-house reliable dedicated facility to study the medicines they use and appraise them regularly in the best interest of the patients.
• This situation warrants a need for a professional service system that could be called “PharmaCare” system that addresses all challenges cited above professionally to support the Healthcare preventive and curative institutions to ensure Professional Drugs logistic system obviating scarcity and loss on one hand & Evidence based therapy and better patient compliance to support the Clinicians.
•👉 Objectives of Pharmacare service
• To achieve:
• Economy with reliable drugs logistics
• Zero Prescription and  medication error
• Zero defect in the drugs delivered
• Improved patient compliance
• Reduced morbidity rate
• Patient’s records that can match with logistic records 
• Streams of Pharmacare service
• Drug Logistics Management (DLM) headed by a Chief Drugs Logistic Pharmacist
• Supportive Clinical Pharmacy Service (SCPS) headed by a Chief Clinical Pharmacist
• 👉Broadly here is how they would be functioning:
• Drug Logistics management (DLM) • Supportive Clinical Pharmacy Service (SCPS)
• Preparation of drugs list with full specification and coding.
• Preparation of Essential list of drugs and quantification
• Budgeting to put forth rational demand
• Defining the stocks for procurement
• Rationale budget management
• Expenditure planning with the available budget
• Defining procurement policy
• Rational inventory management as per priority classification
• Distribution management
• Qualitative dispensing
• Standard Operating Procedure
• total quality management • Preparation of STG, EDL, Formulary
• Supportive service to clinician
• Patient counseling and assistance
• Pharmacovigilance program
• ADR monitoring, reporting and evaluation
• Drug efficacy evaluation in vivo – to eliminate ineffective drugs from the hospital formulary and stocks
• Study of product literatures and technical  interaction with Pharma representatives
• Develop standard facility and SOP as per the Act & Rules  for clinical trials with due safeguards for the volunteers 
• Total quality management
• 👉Benefits to Clinicians
• Hassle-free supply of reliable approved drugs & formulations  
• Lessened brain burden on Clinicians as clinical pharmacist would be supporting with case specific drug information 
• Pin pointed prescription and minimized ADRs
• Counseling service by clinical pharmacists to each patient on medication regimen
• Separate patient’s medication record– helps in follow up and in avoiding allergic molecules
• In-vivo efficacy evaluation of drug molecules helps in avoiding ineffective drug formulations that saves the time of the clinician as well as that of the patient.
• Clinicians can relax and focus on much higher and finer medical issues and follow-up measures
• Reduced morbidity that increases clinician’s rapport
• Clinic-guided procurement mode 
• Benefits to the hospital
• More drugs turn-over with lesser budget
• Medicines at a competitive price
• Nil wastage of drugs due to expiry / idling stock due to  Clinic-guided procurement mode
• Reduced hospital stay that increases hospital rapport
• Minimized local panic purchase
• Zero stock of  ineffective and irrational formulations
• Benefits to the patient
• Availability and accessibility of all required drugs
• Minimum hospitalization as the system facilitates case specific well-judged pin pointed prescription that reduces manpower loss
• Counseling service by clinical pharmacists to each patient on medication regimen
• Minimizes medication trials
• Boosts patient confidence, improves trust in healthcare system, improve drug adherence
• Improved overall quality-of-life of patient and family
• Manpower and other infrastructure required:
• True, any new hither to non existing professional system warrants additional manpower and updating the skill and knowledge of the existing manpower.
• The existing pharmacy manpower would be fully utilized with due recognition and empowerment. 👉👉👉Besides, we need to employ certain specialized category of Pharmacist and post them with due empowerment to make them serve with responsibility and accountability.
• 👉Here I propose the following organogram for establishing Pharmacare Department in each Hospital: Drug Logistics Management (DLM) headed by a Chief Drugs Logistic Pharmacist (CDLP) and Supportive Clinical Pharmacy Service (SCPS) headed by a Chief Clinical Pharmacist
• Every hospital with a minimum of 100 beds should have a full-fledged Pharmacare department.
• The Pharmacy staff structure for a 100 bed hospital should be:
• Drugs Logistic stream:
• Chief Drugs Logistic Pharmacist (CDLP) - {Reporting to Medical Director of the hospital}
• Chief Pharmacist 1
• Pharmacists 8 ( 2*2 for main and sub stores & 2 + 2 for dispensing)
• One Clerical executive to assist CDLP as secretarial support)
• Supportive Clinical Pharmacy Service:
• Chief Clinical Pharmacist  1 {Reporting to Medical Director of the hospital}
• Unit Clinical Pharmacist  One for each Unit.
• Chief Pharmacist – One for each Unit to assist Unit Clinical Pharmacist
•  Pharmacist – One for each unit.
• Three Secretarial executive to Chief Clinical Pharmacist
• NB: All Chief pharmacists and Pharmacists are interchangeable between Logistic and clinical pharmacy streams.
• Well, I have tried to inject the Healthcare system with a professional PharmaCare management keeping all aspects of hospital management in view out of my experience, observations, prevailing strength and weakness of the hospitals, their existing managerial burden, freedom required to clinicians and administrators and to the pharmacists to serve with due accountability for patients safety..
• I wish this will materialize.
• <<<>>>

Note : This must create employment for Pharma D/(PB)  and M.Pharm Pharmacy Practice graduates as well . (Not only for M.D Pharmacologist )

Tuesday, 23 July 2024

Pharmacovigilance committee to draw roadmap for PVPI programme shortly

The first meeting of the National Coordinating Centre (NCC) for Pharmacovigilance Programme of India (PvPI) will be held on February 15 at Indian Council of Medial Research (ICMR) in Delhi. The meeting assumes significance as it will discuss some of the pressing matters that needs that have to be focused to make the PvPI more effective in future.
Dr G N Singh, secretary and scientific director of Indian Pharmacopoeia Commission (IPC), nodal agency for the PvPI, informed that this meeting will be of high importance as the meeting is aimed at discussing future course of the PvPI programme of the country, so that it will enable safe and judicious use of medicines by effectively monitoring adverse drug reactions (ADR's) of the same on the Indian population.
The meeting will be chaired by Dr V M Katoch who is the secretary of the Department of Health Research and also the director general of ICMR and will be attended by 14 members of the NCC committee, which was set up by the union health ministry last year. 
“Our main agenda would be to discuss drafting of new roadmap for the PvPI programme, so that we can also generate independent data on the safety of medicines that will be at par with global drug safety monitoring standards. Apart from that, we will also be discussing other important aspects focusing on the current issues with respect to PvPI so that we can adopt more progressive approach towards strengthening it,” said Dr Singh.
Another important issue that will be discussed during this meet is how to distribute the funds for the PvPI programme in the coming financial year. According to reports, the government has demanded the Planning Commission (PC) to allot Rs.2 crore specifically for the programme in the 12th Five Year Plan from 2012 to 2017. 
However Dr Singh informed that major chunk of the funds if allotted will be invested to hire qualified manpower specifically dedicated to help in improving the delivery of services of the PvPI and also at upgrading the infrastructure accordingly. 
With respect to increasing the number of ADR centres across the country, Dr Singh informed that for the time being, IPC will not be adding new ADR centres to take part in the PvPI, as the government has limited the number to 75 for the current financial year. Recently the government had announced that they do not intent to increase the number of ADR centres in this financial year beyond 75 centres, due to lack of capacity and manpower.
At present, there are 62 ADR centres established across the country, in phased manner, to monitor ADRs in the Indian population and create awareness amongst healthcare professionals about the importance of ADR reporting in India. Initiatives are being taken by the IPC to add 13 new ADR monitoring centres across the country by March 2012, which will make the total count to 75.
Source: PB

The Pharmacovigilance Programme of India (PvPI) is an Indian government organization which identifies and responds to drug safety problems.[1] Its activities include receiving reports of adverse drug events and taking necessary action to remedy problems.[1] The Central Drugs Standard Control Organisation established the program in July 2010 [1][2] with All India Institute of Medical Sciences, New Delhi as the National Coordination Centre, which later shifted to Indian Pharmacopoeia Commission in Ghaziabad on 15 April 2011.

History

Many developed countries set up their pharmacovigilance programs following the Thalidomide scandal in the 1960s.[2] India set up its program in the 1980s.[2] This general concept of drug safety monitoring went through different forms, but the Central Drugs Standard Control Organisation established the present Pharmacovigilance Program of India in 2010.[2] Now the program is well integrated with government legislation, a regulator as leader, and a research center as part of the Indian Pharmacopoeia Commission.


Activities

As of 2018 there were 250 centers around India capable of responding to reports of serious adverse reactions.[2] One of the challenges of the organization is training doctors and hospitals to report adverse drug reactions when patients have them.[3] The Pharmacovigilance Program makes these reports itself, but ideally, such reports could originate from any clinic.[3] The Pharmacovigilance Programme seeks to encourage a culture and social expectation of reporting drug problems.[3]

One of the successes of the program was detecting adverse effects of people in India using carbamazepine.[3][4] While this drug is safer among people native to the Europe, people of South Asia have different genetics and are more likely to experience problems when using it.[3][4] Other countries could not have been able to detect this problem, and the Pharmacovigilance Programme's detection of it was a success story


Collaboration


The establishment of the Pharmacovigilance Program made India a more attractive international destination for foreign companies to bring clinical trials research.[5] Understanding the quality of India's pharmacovigilance programme is key to international researchers conducting trials in India.[6]

The program collaborates both in India and internationally with the World Health Organization on projects for safe medication.[7][2] As a collaborating center, the Pharmacovigilance Programme assists the WHO in developing international policy for other countries to manage their own drug safety programs.[7]

While the United States and Europe have pharmacovigilance systems which are developed well in some ways, the Indian programme has more and specialized expertise to apply for the unique circumstances of India.[8] The Pharmaceutical industry in India produces more drugs than any other national industry.[8] Because of the large amount of drugs and the many countries which import them, the Indian program monitors in some ways more than anywhere else.

Note : PVPI must create employment for Pharma D/(PB)  and M.Pharm Pharmacy Practice graduates as well . (Not only for M.D Pharmacologist )




Monday, 22 July 2024

Mismatches in the inter related Acts have ruined the Profession & Professionals 😢

Mismatches in the inter related Acts have ruined the Profession & Professionals 😢

POV : Bhagwan PS
Retired Deputy Director Pharmacy, Karnataka, India

Why no recognition to Pharmacists? Are We worth or Worthless?

Why no recognition to Pharmacists?

1. Pharmacists who have served have not proved their special knowledge and proved to be indispensable in their foot prints in any sector.

2. Lets realize that Pharmacy has never been and is not a special course as was projected by PCI and IPA. It is like any other science course.

3. They get recognition on their worth.

#WeAndOurWorth 

The PCI has milled out 4 courses in pharmacy and lakhs and lakhs of Pharmacists from Dpharm to PharmD since over 7 decades.

The D pharm was started supported by regulatory under a strong belief that statuory regulation (Section 42 of Ph Act and 65 of D&C Act ) would take care of the emplyment prospects.

PCI did not have any demographic data.

Huge figures (!) calculated on non existant ratio of population against pharmacist was and is being puforth fom the Ac chambers to convince the need but the same zeal was not sustained to ensure professional empowered service at the ground level.

Then onwards, the PCI and the Regultory never looked back to understand the purpose or looked down at the ground level to understand and #Audit their performance and achievement.

Tricky situation is there is no #FeasibilityStudy report and #BenchMarks in PCI planning and implementation to compare and audit the performance and achievement.

Because of this there has been sequence of setbacks and onslaught on the profession in every sector including academy:

1.  The legal provisions instead of being used to empower pharmacist to provide professional service to the public has become an additional means obstacles for exploitation and corruption.

2. The reported existence of more licensed Chemists, Warehoses and hospital dispenseries than the no of Reg Ph in the State is a big evidence to say regulatory is malfunctioning and is abetting a punishable offence.

3.The students who are coming out as pharmaciists with great dreams are leading a miserable life due to unemplyment and under-employment.

4. This has lead to 'Renting' of their certificate so that they can earn additionally in some other jobs, as the professional misconduct is well accommodated by the regulatory.

5. The Indian pharma academe is deaf to repeated cry or call of the industry and healthcare that they need much better knowledgeable and skilled and smart  pharmacists.

6. New courses are started with no basic feasibility study and understanding of the required course content and without involving the key stakeholders like MCI, hospital pharmacists and Industrial experts.

7. B pharms are failing to compete with BSc / MSc Biotechnology in industry.

8. B pharms and M pharms. lack basic knowledge of healthcare needs and market knowledge and logistics technique.

9. All fail in marketing task and corporate employment interview due to over-dumb atmosphere in the campus and lack of smartness on one hand and they quit the job being unable to match with required performance and its audit.

- Only safe job appears to be Teaching where performance is not a criteria and seldom audited. One is safe as long as he can load the marksheet.

10 Online trading and the thinking in some quarters for part time pharmacists are nothing but "' FlSHING-IN-TOROUBLED-WATER'.

11. The legally mandatorily needed Pharmacists are not getting positions and empowerment in the healthcare and regulatory has been failing to support the empowerment of the pharmacists.

12. The National Health Policy document has ignored the profession.

13. Pharmacy is an orphaned profession at the National and State management level with dumb pharmacists at the helm of affairs who have developped acquired passion to talk on global scenario than on the local ground reality.

Well I am feeling guilty of playing 'Blame game'. 

Karnataka state was the only state with Hospital  Pharmacy having DPharm, BPharm and PGs in health sector since 1974.

It was a best opportunity to understand the reality and needs. But, none of us were taken into confidence and our knowledge and skill input was not taken.

Irony was the State council and State Govt nomination to PCI had become a monopoly of Drugs Control department and their subsidiary - The Traders.

Dear PCI, State Councils & Drugs Regulators,
Please understand my appeal to wakeup and workout for  the millions of children who have and are becoming pharmacists and are seeing DEAD WALL before them.

Otherwise even God will not forgive

Good wishes.


POV : Bhagwan PS
Retired Deputy Director Pharmacy, Karnataka, India

Thursday, 18 July 2024

#QualityOfPharmacist Depends on #QualityOfPharmacyCouncil.

As You Sow So You Reap 👍

👉Quality of Council depends on Pharmacists.

👉Quality of Pharmacist depends on Quality of Academy management.

👉Quality of Academy management depends on Quality of Regulatory the PCI.

👉Quality of Regulatory depends on Quality of  Regulatory Functionaries

Therefore #QualityOfPharmacist Depends on #QualityOfPharmacyCouncil.

👉Under the circumstances, How do we get #IntellectualSmartPharmacists to serve as:
 1) Pharmacist
 2) Drugs Regulatory Officers
 3) Council members
 4) Council Registrars
 5) Hospital Pharmacists
 6) Retail & Wholesale Pharmacists
 7) Clinical Pharmacists
 8) Community Pharmacists

Therefore, Councils should be Administered and Managed by a Good Administrator.

Administrator (Registrar) should be on merit of capability and not by democratic process.

POV- Bhagwan PS